Inhibition of Src Tyrosine Kinase Impairs Inherent and Acquired Gemcitabine Resistance in Human Pancreatic Adenocarcinoma Cells

Clinical Cancer Research

Volumn 10, Issue 7, 2004, Pages 2307-2318

  Duxbury, Mark S ^a   Ito, Hiromichi ^a   Zinner, Michael J ^a   Ashley, Stanley W ^a   Whang, Edward E ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; CASPASE; GEMCITABINE; PROPIDIUM IODIDE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RIBONUCLEOTIDE REDUCTASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; GEL MOBILITY SHIFT ASSAY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MALE; METASTASIS; MOUSE; NONHUMAN; NORTHERN BLOTTING; NUDE MOUSE; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR GROWTH; TUMOR XENOGRAFT; WESTERN BLOTTING;

ADENOCARCINOMA; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, NORTHERN; BLOTTING, WESTERN; CASPASES; CELL CYCLE PROTEINS; CELL DIVISION; CELL LINE, TUMOR; CELL NUCLEUS; DEOXYCYTIDINE; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; E2F TRANSCRIPTION FACTORS; E2F1 TRANSCRIPTION FACTOR; GENES, DOMINANT; HUMANS; INHIBITORY CONCENTRATION 50; MICE; MICE, NUDE; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; PANCREATIC NEOPLASMS; PHOSPHORYLATION; PYRIMIDINES; RIBONUCLEOSIDE DIPHOSPHATE REDUCTASE; SRC-FAMILY KINASES; TRANSCRIPTION FACTORS; TYROSINE;

EID: 1642551021     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-1183-3     Document Type: Article

References (60)

1. Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
2. Farrell TJ, Barbot DJ, Rosato FE. Pancreatic resection combined with intraoperative radiation therapy for pancreatic cancer. Ann Surg 1997;226:66-9.
3. Klein B, Sadikov E, Mishaeli M, Levin I, Figer A. Comparison of 5-FU and leucovorin to gemcitabine in the treatment of pancreatic cancer. Oncol Rep 2000;7:875-7.
4. Levitzki A. Tyrosine kinases as targets for cancer therapy. Eur. J. Cancer 2002;38(Suppl 5):S11-8.
5. Xiong HQ, Abbruzzese JL. Epidermal growth factor receptor-targeted therapy for pancreatic cancer. Semin Oncol 2002;29:31-7.
6. Martin GS. The hunting of the Src. Nat Rev Mol Cell Biol 2001;2: 467-75.
7. Boyer B, Bourgeois Y, Poupon MF. Src kinase contributes to the metastatic spread of carcinoma cells. Oncogene 2002;21:2347-56.
8. Pories SE, Hess DT, Swenson K, et al. Overexpression of pp60c-src elicits invasive behavior in rat colon epithelial cells Gastroenterology 1998;114:1287-95.
9. Lutz MP, Esser IB, Flossmann-Kast BB, et al. Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma. Biochem Biophys Res Commun 1998;243:503-8.
10. Menke A, Philippi C, Vogelmann R, et al. Down-regulation of E-cadherin gene expression by collagen type I and type III in pancreatic cancer cell lines. Cancer Res 2001;61:3508-17.
11. Berrozpe G, Schaeffer J, Peinado MA, Real FX, Perucho M. Comparative analysis of mutations in the p53 and K-ras genes in pancreatic cancer. Int J Cancer 1994;58:185-91.
12. Sun C, Yamato T, Furukawa T, et al. Characterization of the mutations of the K-ras, p53, p16, and SMAD4 genes in 15 human pancreatic cancer cell lines. Oncol Rep 2001;8:89-92.
13. Goan YG, Zhou B, Hu E, Mi S, Yen Y. Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line. Cancer Res 1999;59:4204-7.
14. Hanke JH, Gardner JP, Dow RL, et al. Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation. J Biol Chem. 1996;271:695-701.
15. Wilson MB, Schreiner SJ, Choi HJ, Kamens J, Smithgall TE. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis. Oncogene 2002;21:8075-88.
16. Raitano AB, Scuderi P, Korc M. Binding and biological effects of tumor necrosis factor and γ interferon in human pancreatic carcinoma cells. Pancreas 1990;5:267-77.
17. Alessi DR, Cohen P. Mechanism of activation and function of protein kinase B. Curr Opin Genet Dev 1998;8:55-62.
18. Downward J. Mechanisms and consequences of activation of protein kinase B/Akt. Curr Opin Cell Biol 1998;10:262-7.
19. Bourguignon LY, Zhu H, Shao L, Chen YW. CD44 interaction with c-Src kinase promotes cortactin-mediated cytoskeleton function and hyaluronic acid-dependent ovarian tumor cell migration. J Biol Chem 2001;276:7327-36.
20. Tan MH, Chu TM. Characterization of the tumorigenic and metastatic properties of a human pancreatic tumor cell line (AsPC-1) implanted orthotopically into nude mice. Tumour Biol 1985;6:89-98.
21. Sun FX, Tohgo A, Bouvet M, et al. Efficacy of camptothecin analog DX-8951f (exatecan mesylate) on human pancreatic cancer in an orthotopic metastatic model. Cancer Res 2003;63:80-5.
22. Flossmann-Kast BB, Jehle PM, Hoeflich A, Adler G, Lutz MP. Src stimulates insulin-like growth factor I (IGF-I)-dependent cell proliferation by increasing IGF-I receptor number in human pancreatic carcinoma cells. Cancer Res 1998;58:3551-4.
23. Nam JS, Ino Y, Sakamoto M, Hirohashi S. Src family kinase inhibitor PP2 restores the E-cadherin/catenin cell adhesion system in human cancer cells and reduces cancer metastasis. Clin Cancer Res 2002;8:2430-6.
24. Eibl G, Wente MN, Reber HA, Hines OJ. Peroxisome proliferator-activated receptor γ induces pancreatic cancer cell apoptosis. Biochem Biophys Res Commun 2001;287:522-9.
25. Wang W, Waters SJ, MacDonald JR, et al. Irofulven (6-hydroxymethylacylfulvene, MGI 114) induces caspase 8 and 9-mediated apoptosis in human pancreatic adenocarcinoma cells. Anticancer Res 2001; 21:1789-94.
26. Perugini RA, McDade TP, Vittimberga FJ Jr, Callery MP. Pancreatic cancer cell proliferation is phosphatidylinositol 3-kinase dependent. J Surg Res 2000;90:39-44.
27. Yao Z, Okabayashi Y, Yutsudo Y, et al. Role of Akt in growth and survival of PANC-1 pancreatic cancer cells. Pancreas 2002;24:42-6.
28. Bondar VM, Sweeney-Gotsch B, Andreeff M, Mills GB, McConkey DJ. Inhibition of the phosphatidylinositol 3′-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Mol Cancer Ther 2002;1:989-97.
29. Farre L, Casanova I, Guerrero S, et al. Heterotopic implantation alters the regulation of apoptosis and the cell cycle and generates a new metastatic site in a human pancreatic tumor xenograft model. FASEB J 2002;16:975-82.
30. Arlt A, Gehrz A, Muerkoster S, et al. Role of NF-′B and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene 2003;22:3243-51.
31. Fahy BN, Schlieman M, Virudachalam S, Bold RJ. AKT inhibition is associated with chemosensitisation in the pancreatic cancer cell line MIA-PaCa-2. Br J Cancer 2003;89:391-7.
32. Ng SS, Tsao MS, Nicklee T, Hedley DW. Wortmannin inhibits pkb/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice. Clin Cancer Res 2001;7:3269-75.
33. Ng SSW, Tsao MS, Chow S, Hedley DW. Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res 2000;60:5451-5.
34. Zhou H, Li XM, Meinkoth J, Pittman RN. Akt regulates cell survival and apoptosis at a postmitochondrial level. J Cell Biol 2000; 151:483-94.
35. Jiang T, Qiu Y. Interaction between Src and a C-terminal proline-rich motif of Akt is required for Akt activation. J Biol Chem 2003;278: 15789-93.
36. Boudny V, Nakano S. Src tyrosine kinase augments taxotere-induced apoptosis through enhanced expression and phosphorylation of Bcl-2. Br J Cancer 2002;86:463-9.
37. Bergman AM, Pinedo HM, Peters GJ. Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine). Drug Resist Updat 2002;5: 19-33.
38. Zhou B, Mo X, Liu X, Qiu W, Yen Y. Human ribonucleotide reductase M2 subunit gene amplification and transcriptional regulation in a homogeneous staining chromosome region responsible for the mechanism of drug resistance. Cytogenet Cell Genet 2001;95:34-42.
39. Zhou BS, Tsai P, Ker R, et al. Overexpression of transfected human ribonucleotide reductase M2 subunit in human cancer cells enhances their invasive potential. Clin Exp Metastasis 1998;16:43-9.
40. 1/S-regulatory genes. Mol Cell Biol 1995;15:4215-24.
41. Irby RB, Yeatman TJ. Role of Src expression and activation in human cancer. Oncogene 2000;19:5636-42.
42. Staley CA, Parikh NU, Gallick GE. Decreased tumorigenicity of a human colon adenocarcinoma cell line by an antisense expression vector specific for c-Src. Cell Growth Differ 1997;8:269-74.
43. Wiener JR, Nakano K, Kruzelock RP, et al. Decreased Src tyrosine kinase activity inhibits malignant human ovarian cancer tumor growth in a nude mouse model. Clin Cancer Res 1999;5:2164-70.
44. Grunewald R, Kantarjian H, Keating MJ, et al. Pharmacologically directed design of the dose rate and schedule of 2′,2′-difluorodeoxycytidine (gemcitabine) administration in leukemia. Cancer Res 1990;50: 6823-6.
45. Thomlinson R, Gray L. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 1955;9:539-49.
46. Cardone MH, Roy N, Stennicke HR, et al. Regulation of cell death protease caspase-9 by phosphorylation. Science (Wash DC) 1998;282: 1318-21.
47. Plunkett W, Huang P, Gandhi V. Preclinical characteristics of gemcitabine. Anticancer Drugs 1995;6(Suppl 6):7-13.
48. Peters GJ, Ruiz van Haperen VW, Bergman AM, et al. Preclinical combination therapy with gemcitabine and mechanisms of resistance. Semin Oncol 1996;23:16-24.
49. Blattner C, Sparks A, Lane D. Transcription factor E2F-1 is up-regulated in response to DNA damage in a manner analogous to that of p53. Mol Cell Biol 1999;19:3704-13.
50. Nahle Z, Polakoff J, Davuluri RV, et al. Direct coupling of the cell cycle and cell death machinery by E2F. Nat. Cell Biol 2002;4: 859-64.
51. Johnson DG. The paradox of E2F1: oncogene and tumor suppressor gene. Mol Carcinog 2000;27:151-7.
52. La Thangue NB. The yin and yang of E2F-1: balancing life and death. Nat Cell Biol 2003;5:587-9.
53. Kowalik TF, DeGregori J, Schwarz JK, Nevins JRE. 2F1 overexpression in quiescent fibroblasts leads to induction of cellular DNA synthesis and apoptosis. J Virol 1995;69:2491-500.
54. Rodicker F, Stiewe T, Zimmermann S, Putzer BM. Therapeutic efficacy of E2F1 in pancreatic cancer correlates with TP73 induction. Cancer Res 2001;61:7052-5.
55. Johnson DG, Schwarz JK, Cress WD, Nevins JR. Expression of transcription factor E2FI induces quiescent cells to enter S phase. Nature (Lond) 1993;365:349-52.
56. Jung CP, Motwani MV, Schwartz GK. Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase M2 subunit. Clin Cancer Res 2001;7:2527-36.
57. Pasteau S, Loiseau L, Brun G. Proliferation of chicken neuroretina cells induced by v-src, in vitro, depends on activation of the E2F transcription factor. Oncogene 1997;15:17-28.
58. Boudny V, Nakano S. Src tyrosine kinase but not activated Ras augments sensitivity to taxanes through apoptosis in human adenocarcinoma cells. Anticancer Res 2003;23:7-12.
59. Fukushima M, Fujioka A, Uchida J, Nakagawa F, Takechi T. Thymidylate synthase (TS) and ribonucleotide reductase (RNR) may be involved in acquired resistance to 5-fluorouracil (5-FU) in human cancer xenografts in vivo. Eur J Cancer 2001;37:1681-7.
60. Kubota T, Watanabe M, Otani Y, Kitajima M, Fukushiuma M. Different pathways of 5-fluorouracil metabolism after continuous venous or bolus injection in patients with colon carcinoma: possible predictive value of thymidylate synthetase mRNA and ribonucleotide reductase for 5-fluorouracil sensitivity. Anticancer Res 2002;22:3537-40.